ARS Pharma has claimed FDA approval for its epinephrine nasal spray neffy, becoming the first needle-free alternative to EpiPen-style autoinjectors for serious allergic reactions.
An alternative to epinephrine autoinjectors that can be delivered by a nasal spray is close to approval in Europe after being recommended for approval by the EMA’s human medicines committee
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
